Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.UnitedHealth is offering financial assistance to providers affected by a cyberattack on Change Healthcare, but providers say it is not enough to cover the financial strain. CVS and Walgreens will begin selling the abortion pill, mifepristone. Hospital compliance with price transparency requirements is declining due to lenient enforcement. The cyberattack on Change Healthcare is causing widespread effects on providers, impacting billing, eligibility checks, prior authorization requests, and prescription fulfillment.In other news, a report shows that 2 out of 3 healthcare firms find their digital transformation efforts ineffective, and a watchdog group highlights the importance of adopting a platform-based strategy in healthcare. This newsletter provides daily news and insights for healthcare leaders and is sponsored by Paylocity, offering HR and payroll software solutions. Healthcare Dive is a publication operated by Industry Dive, providing in-depth journalism and insight into the most impactful news and trends shaping healthcare.Pfizer's decision to focus on biologics over small molecules in its oncology strategy was influenced by the Inflation Reduction Act. This act's drug price negotiation provisions led Pfizer to build up its biologics portfolio and reduce small molecules. Meanwhile, new ALS treatments are facing regulatory uncertainty despite the approval of two novel therapies for the disease.The ALS treatment landscape is filled with over 100 candidates, and experts suggest that regulatory standards and expectations are still evolving. Bayer paid $310 million to BridgeBio for an ATTR-CM treatment in Europe as BridgeBio's Acoramidis nears an FDA approval decision. Additionally, Akero Therapeutics' Efruxifermin showed positive mid-stage fibrosis data, improving fibrosis without worsening metabolic dysfunction-associated steatohepatitis.The text also mentions other news in the biopharma industry, such as J&J's full FDA approval for Rybrevant and a pilot study showing that better eConsents create better human experiences. Finally, it promotes registration for Bio 2024, the world's largest biotech event, where leaders in business, science, and policy can come together for innovation and partnering opportunities.